Please assess the completion status of the following clinical trial:

Trial Title: Switch From Tenofovir to Raltegravir for Low Bone Mineral Density

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. provision of written, informed consent~2. HIV-infected adults at least 18 years of age~3. receiving stable ART including TDF and a r/PI for the previous 6 months~4. no prior PI genotypic resistance or known replication of HIV in patients receiving a PI~5. plasma HIV RNA \< 50 copies/ml for at least the previous 3 months~6. spine or neck of femur t-score ≤ -1.0 (i.e. WHO-defined osteopenia) measured by dual energy x-ray absorptiometry (DEXA)~   Exclusion Criteria:~7. participation in any other clinical trial (unless approved by the study PI)~8. use of TDF for previously active chronic hepatitis B infection~9. receiving or requiring therapy for low BMD (including prior fragility fracture)~10. using oral corticosteroids or inhaled fluticasone~11. virological failure on, or intolerance to, RAL~12. contra-indication to RAL therapy (see appendix 2)~13. breast-feeding~14. pregnancy~15. secondary, endocrinological cause of low BMD:25-hydroxy vitamin D deficiency, hypogonadism: a)symptomatic b)asymptomatic defined by total testosterone \> 25% below lower limit of reference range and/or luteinizing hormone \> 2 x upper limit of normal (ULN),untreated hypothyroidism or hyperparathyroidism according to local reference ranges

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Raltegravir (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).